Proposed joint venture with the China National Medical Corp. covers the production of ribavirin in the Peoples Republic, where hepatitis and hemorrhagic fever -- both treated by the drug -- are endemic; some 100 mil. Chinese are estimated to carry some form of hepatitis virus. The joint venture will initially produce 10,000 kg of ribavirin annually, of which ICN will purchase at least 50%. ICN will also assist CNMC to improve marketing and distribution of the drug and to boost its acceptance in the medical community.
You may also be interested in...
October and November 2020 were bad months for companies seeking to have their planned EU filings fast-tracked through the centralized drug review system at the European Medicines Agency.
Tactic aims to allow incoming Administration to scrutinize so-called ‘midnight rules’ issued in the final days of the Trump Administration before they take effect. Regulators may also solicit stakeholder comments on delayed rules.
Device companies operating in Canada are being advised to review their internal procedures in anticipation of new postmarket requirements that come into force this year.